

# Members Obtain Free CE Credits from JCP Articles!



## ***Population Pharmacokinetic Simulations for Dose Optimization of Tenofovir Disoproxil Fumarate in HIV-Infected Patients with Moderate-to-Severe Renal Impairment***

April 2025 – *The Journal of Clinical Pharmacology* (JCP)

### **Why is this article important to you?**

Learners that complete this activity will learn how population pharmacokinetic (PPK) models were used to optimize tenofovir disoproxil fumarate (TDF) dosing regimens for HIV-infected patients with renal impairment. This activity will cover strategies to determine dose optimization of TDF using PPK simulations for HIV-infected patients with moderate to severe renal impairment.



### **ACPE Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

**UAN:** 0665-0000-25-005-H01-P – ACPE 1 Contact Hours

**Activity Type:** Knowledge-based **Format:** Home-study **Target Audience:** 'P'



**ACCME**  
ACCREDITED

### **ACCME Accreditation Statement**

The American College of Clinical Pharmacology® is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

### **ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1™* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

### **Target Audience**

Interprofessional team of Physicians, Pharmacists, PhDs and other healthcare professionals interested in expanding their knowledge on dosing regimens for HIV-infected patients with renal impairment.

### **Learning Objectives**

After completing this activity, the learner will be able to:

1. Explain the current dosing regimen for HIV-infected patients with moderate to severe renal impairment;
2. List the models that best describe the concentration-time profiles and the main covariates;
3. Identify the target  $C_{min}$  associated with effective viral suppression and prevention of HIV and the supratherapeutic levels associated with nephrotoxicity  $C_{12}$  target concentration;
4. Describe the recommended TDF dosing regimens for patients with varying degrees of renal impairment.

### **Requirements to Receive Credit**

In order to receive continuing medical education (CME) or continuing pharmacy education (CPE) credit, the learner must register for the educational activity, study the provided journal article, complete the online learning Self-assessment Post-test as well as the online course Evaluation and CME/CPE Certificate. Credits and CME/CPE Certificates must be claimed within thirty (30) days of completing the article, Post-test and Evaluation. Contact [CE@ACCP1.org](mailto:CE@ACCP1.org) with any questions.

**Disclosures:**

Article Selection: John van den Anker, MD, PhD, Editor-in-Chief, JCP, selected the article for this course and has nothing to disclose.

Planner: Kenneth Der, BS, Associate Director, Amgen Inc, planned the continuing education documentation for this course and all of the relevant financial relationships listed for this individual have been mitigated.

CE Reviewer: Anjali Kumari, PhD, Postdoctoral Fellow, Univ of Louisville, served as the CE Reviewer and has nothing to disclose.

**Schedule & Fees**

JCP monthly Journal CE articles are generally released on the 1<sup>st</sup> or 2<sup>nd</sup> Tuesday of each month. They are priced in packages of January to December for each year. Packages are available at no cost to ACCP Members and \$75/calendar year to Non-members. Once you register, you have access to all of the Journal CE articles for the calendar year.

**Acknowledgement of Financial Support**

No financial support was received for this educational activity.

**Home Study Initial Release and Expiration Dates**

**Date of Issuance:** 4/1/2025

**Expiration Date:** 4/1/2028

**Online Location:**

[https://accp1.org/Members/ACCP1/4Continuing\\_Education/Journal\\_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14](https://accp1.org/Members/ACCP1/4Continuing_Education/Journal_CE.aspx?hkey=adecf2ad-e111-4e26-92b5-bbd8ce8fda14)